Patents Assigned to APTABIO THERAPEUTICS INC.
-
Patent number: 11999718Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.Type: GrantFiled: January 6, 2023Date of Patent: June 4, 2024Assignee: APTABIO THERAPEUTICS INC.Inventors: Soo Jin Lee, Sung Hwan Moon, Sooho Ban, Eunsil Lee, Eun Jung Shin, Yoo-Kyung Goh
-
Publication number: 20230201179Abstract: A method of protecting a kidney by reducing contrast media-induced nephrotoxicity or for preventing or treating contrast media-induced acute kidney injury is disclosed.Type: ApplicationFiled: March 23, 2021Publication date: June 29, 2023Applicant: APTABIO THERAPEUTICS INC.Inventors: Soo Jin LEE, Sung Hwan MOON
-
Publication number: 20230192752Abstract: Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-?-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: November 30, 2018Publication date: June 22, 2023Applicants: Aptabio Therapeutics Inc., Samjin Pharmaceutical Co., Ltd.Inventors: Sung Hwan Moon, Soo Jin Lee, Yu Mi Ji, Hee Jong Shin, Min Hyo Ki, Yong Bin Park, Ji Hyun Um
-
Publication number: 20230148365Abstract: A pharmaceutical composition or an antiviral agent for the treatment of pulmonary fibrosis is disclosed. The composition or the antiviral agent contains a compound of Formula 1, which is a pyrazole derivative, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 23, 2021Publication date: May 11, 2023Applicant: APTABIO THERAPEUTICS INC.Inventors: Sung Hwan MOON, Soo Jin LEE, Hyunkyung YU, Yoo-Kyung GOH
-
Publication number: 20230025836Abstract: The present invention relates to an ophthalmic preparation containing an active ingredient selected from 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol compound or a pharmaceutically acceptable salt thereof. The eye drop according to the present invention is excellent in stability and safety and shows an excellent effect on prevention or treatment of eye diseases in such a way that an active ingredient thereof reaches a posterior segment of an eyeball simply through instillation rather than a direct injection into an eyeball.Type: ApplicationFiled: November 20, 2020Publication date: January 26, 2023Applicants: Samjin Pharmaceutical Co., Ltd., AptaBio Therapeutics Inc.Inventors: Min-hyo Ki, Jin-cheul Kim, Mee-Hwa Choi, Dong-Ha Lee, Sung Hwan Moon, Soo Jin Lee
-
Publication number: 20220218685Abstract: The present invention relates to a composition for treating eye diseases, wherein the composition comprises a pyrazole-based compound, which is a pharmacologically active substance, and a biodegradable polymer, so that a drug effectively reaches a posterior segment of an eyeball, while prolonging an action time of the drug administered into the eyeball.Type: ApplicationFiled: May 29, 2020Publication date: July 14, 2022Applicants: Samjin Pharmaceutical Co., Ltd., AptaBio Therapeutics Inc.Inventors: Min-hyo Ki, Kyung-wan Nam, Jin-cheul Kim, Kyung-jin Ahn, Sung Hwan Moon, Soo Jin Lee
-
Patent number: 11174240Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.Type: GrantFiled: April 20, 2018Date of Patent: November 16, 2021Assignee: Aptabio Therapeutics Inc.Inventors: Sung Hwan Moon, Soo Jin Lee, Sung Chan Lee
-
NOVEL CRYSTALLINE SOLID COMPOUND OF 3-PHENYL-4-PROPYL-1-(PYRIDIN-2-YL)-1H-PYRAZOL-5-OL HYDROCHLORIDE
Publication number: 20210122726Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.Type: ApplicationFiled: April 20, 2018Publication date: April 29, 2021Applicant: Aptabio Therapeutics Inc.Inventors: Sung Hwan Moon, Soo Jin Lee, Sung Chan Lee -
Patent number: 10966969Abstract: Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.Type: GrantFiled: September 14, 2018Date of Patent: April 6, 2021Assignee: APTABIO THERAPEUTICS INC.Inventors: Sung Hwan Moon, Soo Jin Lee, Sung Chan Lee, Yun Soo Bae
-
Publication number: 20200390752Abstract: Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.Type: ApplicationFiled: September 14, 2018Publication date: December 17, 2020Applicant: APTABIO THERAPEUTICS INC.Inventors: Sung Hwan Moon, Soo Jin Lee, Sung Chan Lee, Yun Soo Bae
-
Patent number: 9056886Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.Type: GrantFiled: June 29, 2010Date of Patent: June 16, 2015Assignee: APTABIO THERAPEUTICS INC.Inventors: Soo Jin Lee, Sung Hwan Moon
-
Publication number: 20120202981Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.Type: ApplicationFiled: June 29, 2010Publication date: August 9, 2012Applicant: APTABIO THERAPEUTICS INC.Inventors: Soo Jin Lee, Sung Hwan Moon